EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting the Ca2+ signaling toolkit as an alternative strategy to mitigate SARS-CoV-2-induced cardiovascular adverse events

Simona Scorza, Valentina Brunetti, Giorgia Scarpellino, Maira Certini, Andrea Gerbino, Francesco Moccia

Vascular Pharmacology · 2025

DOI: 10.1016/j.vph.2024.107458 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2025. Verfasst von Simona Scorza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari "Aldo Moro", Bari, Italy. Hauptthemen laut MEDLINE: COVID-19, Calcium Signaling, Cardiovascular Diseases, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 87 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ca2+ signaling events are essential for maintaining cardiovascular health, regulating critical functions in both endothelial and cardiac cells. SARS-CoV-2 infection impinges this delicate balance, leading to severe cardiovascular complications. SARS-CoV-2 binds to the ACE2 receptor on endothelial and cardiomyocyte surfaces, triggering abnormal increases in intracellular Ca2+ levels that promote endothelial dysfunction, inflammation, and hypercoagulation. In endothelial cells, this dysregulation activates a pro-inflammatory state and compromises vascular integrity. In cardiomyocytes, SARS-CoV-2-induced Ca2+ imbalances contribute to arrhythmias and heart failure by promoting abnormal Ca2+ cycling and energy metabolism disruptions. Additionally, the cytokine storm associated with COVID-19 amplifies these effects by further altering Ca2+ handling, enhancing inflammatory responses, and promoting thrombosis. Targeting Ca2+ channels, particularly endolysosomal two-pore channels, represents a promising therapeutic approach to counteract SARS-CoV-2's effects on Ca2+ dynamics. Several FDA-approved drugs that modulate Ca2+ signaling could be repurposed to prevent viral entry and mitigate cardiovascular damage. Understanding these Ca2+-related mechanisms offers valuable insights for developing treatments to reduce cardiovascular risk in COVID-19 and potentially future viral infections impacting the cardiovascular system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Calcium SignalingCardiovascular DiseasesSARS-CoV-2COVID-19 Drug TreatmentCalcium Channel BlockersHumansAnimalsMyocytes, CardiacCalcium Channels

Stichwörter der Autor:innen

COVID-19Ca2+ SignalingCardiomyocytesCytokine stormEndothelial cellsPiezo1 ChannelsRyR2Two-Pore Channels

Substanzen

Calcium Channel BlockersCalcium Channels

Autor:innen und Institutionen

  • Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari "Aldo Moro", Bari, Italy.
  • Laboratory of General Physiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
  • Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari "Aldo Moro", Bari, Italy. Electronic address: andrea.gerbino@uniba.it.
  • Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy. Electronic address: francesco.moccia@unimol.it.

Zitieren

APA

Scorza, S., Brunetti, V., Scarpellino, G., Certini, M., Gerbino, A., & Moccia, F. (2025). Targeting the Ca2+ signaling toolkit as an alternative strategy to mitigate SARS-CoV-2-induced cardiovascular adverse events. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2024.107458

Vancouver

Scorza S, Brunetti V, Scarpellino G, Certini M, Gerbino A, Moccia F. Targeting the Ca2+ signaling toolkit as an alternative strategy to mitigate SARS-CoV-2-induced cardiovascular adverse events. Vascular Pharmacology. 2025. doi:10.1016/j.vph.2024.107458

BibTeX
@article{Scorza2025,
  author = {Scorza, Simona and Brunetti, Valentina and Scarpellino, Giorgia and Certini, Maira and Gerbino, Andrea and Moccia, Francesco},
  title = {Targeting the Ca2+ signaling toolkit as an alternative strategy to mitigate SARS-CoV-2-induced cardiovascular adverse events},
  journal = {Vascular Pharmacology},
  year = {2025},
  doi = {10.1016/j.vph.2024.107458}
}
Kostenlos starten →